MN-166

ibudilast · MediciNova

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MN-166, covering 2024-09-24 to 2024-09-24. Get the full timeline:

Most recent: Clinical Trial Update: A Biomarker Study to Evaluate MN-166 in Subjects With Amyotrophic Literal Sclerosis (ALS) [Phase 1, Phase 2]